Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Oct 31;15(5):2358-2362.
doi: 10.21037/jgo-24-373. Epub 2024 Oct 9.

DNA-dependent protein kinase inhibitor as a sensitizer of radiotherapy in locally advanced rectal cancer

Yoshinori Kagawa  1   2 , Jun Watanabe  3 , Koji Ando  4
Affiliations
Editorial

DNA-dependent protein kinase inhibitor as a sensitizer of radiotherapy in locally advanced rectal cancer

Yoshinori Kagawa et al. J Gastrointest Oncol. .
No abstract available

Keywords: DNA damage repair (DDR); DNA-dependent protein kinase inhibitor (DNA-PK inhibitor); Locally advanced rectal cancer (LARC).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://jgo.amegroups.com/article/view/10.21037/jgo-24-373/coif). Y.K. discloses payment or honoraria from Lilly, Sanofi, Takeda, Merck, Taiho, MSD, Chugai, Bayer, and Ono. J.W. reports receiving honoraria for lectures from Johnson and Johnson, Medtronic, Eli Lilly and Takeda Pharmaceuticals, and receiving research funding from Medtronic, TERUMO and Stryker Japan outside the submitted work. The other author has no conflicts of interest to declare.

Comment on

References

    1. Kagawa Y, Smith JJ, Fokas E, et al. Future direction of total neoadjuvant therapy for locally advanced rectal cancer. Nat Rev Gastroenterol Hepatol 2024;21:444-55. 10.1038/s41575-024-00900-9 - DOI - PMC - PubMed
    1. Garcia-Aguilar J, Patil S, Kim JK, et al. Preliminary results of the organ preservation of rectal adenocarcinoma (OPRA) trial. J Clin Oncol 2020;38:4008. 10.1200/JCO.2020.38.15_suppl.4008 - DOI
    1. Romesser PB, Capdevila J, Garcia-Carbonero R, et al. A Phase Ib Study of the DNA-PK Inhibitor Peposertib Combined with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer. Clin Cancer Res 2024;30:695-702. 10.1158/1078-0432.CCR-23-1129 - DOI - PMC - PubMed
    1. Zenke FT, Zimmermann A, Sirrenberg C, et al. Pharmacologic Inhibitor of DNA-PK, M3814, Potentiates Radiotherapy and Regresses Human Tumors in Mouse Models. Mol Cancer Ther 2020;19:1091-101. 10.1158/1535-7163.MCT-19-0734 - DOI - PubMed
    1. Groelly FJ, Fawkes M, Dagg RA, et al. Targeting DNA damage response pathways in cancer. Nat Rev Cancer 2023;23:78-94. 10.1038/s41568-022-00535-5 - DOI - PubMed

LinkOut - more resources